JP2015505823A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505823A5
JP2015505823A5 JP2014543617A JP2014543617A JP2015505823A5 JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5 JP 2014543617 A JP2014543617 A JP 2014543617A JP 2014543617 A JP2014543617 A JP 2014543617A JP 2015505823 A5 JP2015505823 A5 JP 2015505823A5
Authority
JP
Japan
Prior art keywords
amyloid
variant
polypeptide
pharmaceutical composition
wild
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014543617A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015505823A (ja
JP6220344B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2012/066793 external-priority patent/WO2013082114A1/en
Publication of JP2015505823A publication Critical patent/JP2015505823A/ja
Publication of JP2015505823A5 publication Critical patent/JP2015505823A5/ja
Application granted granted Critical
Publication of JP6220344B2 publication Critical patent/JP6220344B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014543617A 2011-11-29 2012-11-28 アミロイド結合剤としてのバクテリオファージのｐ３の使用 Active JP6220344B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564602P 2011-11-29 2011-11-29
US61/564,602 2011-11-29
US201261708709P 2012-10-02 2012-10-02
US61/708,709 2012-10-02
US201261730316P 2012-11-27 2012-11-27
US61/730,316 2012-11-27
PCT/US2012/066793 WO2013082114A1 (en) 2011-11-29 2012-11-28 Use of p3 of bacteriophage as amyloid binding agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017074284A Division JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Publications (3)

Publication Number Publication Date
JP2015505823A JP2015505823A (ja) 2015-02-26
JP2015505823A5 true JP2015505823A5 (https=) 2015-12-03
JP6220344B2 JP6220344B2 (ja) 2017-10-25

Family

ID=47326403

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014543617A Active JP6220344B2 (ja) 2011-11-29 2012-11-28 アミロイド結合剤としてのバクテリオファージのｐ３の使用
JP2017074284A Active JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017074284A Active JP6440765B2 (ja) 2011-11-29 2017-04-04 アミロイド結合剤としてのバクテリオファージのｐ３の使用

Country Status (16)

Country Link
US (3) US9493515B2 (https=)
EP (1) EP2785364B1 (https=)
JP (2) JP6220344B2 (https=)
KR (1) KR20140100543A (https=)
CN (2) CN104093414A (https=)
AU (1) AU2012346056B2 (https=)
BR (1) BR112014013086A2 (https=)
CA (1) CA2857539C (https=)
EA (2) EA201792608A3 (https=)
IL (1) IL232867B (https=)
IN (1) IN2014CN04587A (https=)
MX (1) MX362175B (https=)
PH (1) PH12014501200A1 (https=)
SG (2) SG10201709849TA (https=)
WO (1) WO2013082114A1 (https=)
ZA (1) ZA201403863B (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) * 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação
WO2017091467A1 (en) * 2015-11-25 2017-06-01 Eli Lilly And Company Phage display vectors and methods of use
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
KR102421210B1 (ko) * 2017-07-14 2022-07-18 지씨이 홀딩 에이비 전자 게이지
WO2019241628A1 (en) * 2018-06-15 2019-12-19 Proclara Biosciences, Inc. General amyloid interaction motif (gaim)
AU2023403257A1 (en) 2022-12-02 2025-06-12 Alzheon, Inc. Methods for treating neurodegenerative disorders with tramiprosate

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3941763A (en) 1975-03-28 1976-03-02 American Home Products Corporation PGlu-D-Met-Trp-Ser-Tyr-D-Ala-Leu-Arg-Pro-Gly-NH2 and intermediates
US4215051A (en) 1979-08-29 1980-07-29 Standard Oil Company (Indiana) Formation, purification and recovery of phthalic anhydride
DE3572982D1 (en) 1984-03-06 1989-10-19 Takeda Chemical Industries Ltd Chemically modified lymphokine and production thereof
WO1990006952A1 (fr) 1988-12-22 1990-06-28 Kirin-Amgen, Inc. Facteur de stimulation de colonies de granulocytes modifies chimiquement
EP0939121B2 (de) 1989-09-12 2007-12-26 AHP Manufacturing B.V. TFN-bindende Proteine
US6552170B1 (en) 1990-04-06 2003-04-22 Amgen Inc. PEGylation reagents and compounds formed therewith
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
ATE240740T1 (de) 1991-03-15 2003-06-15 Amgen Inc Pegylation von polypeptiden
FR2686899B1 (fr) 1992-01-31 1995-09-01 Rhone Poulenc Rorer Sa Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant.
ATE311895T1 (de) 1992-05-26 2005-12-15 Immunex Corp Neue zytokine die cd30 binden
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
AU776910B2 (en) 1998-12-08 2004-09-23 Merck Patent Gesellschaft Mit Beschrankter Haftung Modifying protein immunogenicity
US20020052311A1 (en) 1999-09-03 2002-05-02 Beka Solomon Methods and compostions for the treatment and/or diagnosis of neurological diseases and disorders
US8022270B2 (en) 2000-07-31 2011-09-20 Biolex Therapeutics, Inc. Expression of biologically active polypeptides in duckweed
CN100522242C (zh) 2001-02-19 2009-08-05 默克专利有限公司 具有降低的免疫原性的人工蛋白质
KR20030082962A (ko) 2001-03-08 2003-10-23 메르크 파텐트 게엠베하 감소된 면역원성을 갖는 개질된과립구대식세포집락자극인자(ｇｍ-ｃｓｆ)
ATE484198T1 (de) 2002-08-20 2010-10-15 Sungene Gmbh & Co Kgaa Verwendung von astaxanthinhaltigen pflanzen oder pflanzenteilen der gattung tagetes als futtermittel
DE10238846A1 (de) * 2002-08-20 2004-03-04 Nemod Immuntherapie Ag Aktive Fusionsproteine und Verfahren zu ihrer Herstellung
DK1853285T3 (da) * 2005-02-01 2011-06-27 Univ Ramot Fremgangsmåde til behandling af inflammation forbundet med amyloidaflejringer og hjerneinflammation som involverer aktiverede mikroglia
EP1959996A2 (en) * 2005-12-12 2008-08-27 AC Immune S.A. Monoclonal antibody
US20090304726A1 (en) 2006-02-15 2009-12-10 Ramot At Tel Aviv University Ltd. Viral display vehicles for treating multiple sclerosis
EP1991261A2 (en) 2006-02-15 2008-11-19 Ramot at Tel-Aviv University Ltd. Filamentous bacteriophage displaying protein as a binder of antibodies and immunocomplexes for delivery to the brain
WO2007109733A2 (en) * 2006-03-21 2007-09-27 The Johns Hopkins University Diagnostic and prognostic markers and treatment strategies for multiple sclerosis
US20090105090A1 (en) * 2006-04-06 2009-04-23 Fumiaki Uchiyama Phage Display By Novel Filamentous Bacteriophage
AU2007275258A1 (en) 2006-07-21 2008-01-24 Ramot At Tel Aviv University Ltd. Use of a phage displaying a peptide from an adhesion protein for treating a disease associated with intracellular formation of protein fibrillar inclusions or aggregates
KR101485202B1 (ko) 2006-10-11 2015-01-22 안티토페 리미티드 Ｔ 세포 에피토프 데이터베이스들
EP2303315A1 (en) * 2008-05-22 2011-04-06 Ramot at Tel Aviv University Ltd. Method for treating disease characterized by plaque
CN102203124A (zh) * 2008-07-25 2011-09-28 雅培制药有限公司 淀粉状蛋白β肽类似物，其寡聚物，用于制备的方法以及包括所述类似物或寡聚物的组合物，及其用途
US20100113304A1 (en) * 2008-09-26 2010-05-06 Wyeth Compatible display vector systems
NZ592928A (en) * 2008-11-24 2012-12-21 Univ Ramot Method for treating parkinson' s disease using filamentous bacteriophage
WO2011084714A2 (en) 2009-12-17 2011-07-14 Biogen Idec Ma Inc. STABILIZED ANTI-TNF-ALPHA scFv MOLECULES OR ANTI-TWEAK scFv MOLECULES AND USES THEREOF
US8856364B2 (en) 2011-03-11 2014-10-07 Google Inc. Conducting opportunistic network updates on a mobile device
WO2012125555A1 (en) 2011-03-11 2012-09-20 Ramot At Tel-Aviv University Ltd. Method for treating neurodegenerative tauopathy
CA2857539C (en) 2011-11-29 2021-08-03 Neurophage Pharmaceuticals, Inc. Bacteriophage gene 3 protein compositions and use as amyloid binding agents
DK2906235T3 (en) 2012-10-02 2017-09-25 Proclara Biosciences Inc USE OF P3 OF BACTERIOPHAGIC FUSION PROTEINS AS AMYLOID BINDING AGENTS
AU2014274253B2 (en) 2013-05-28 2018-06-14 Proclara Biosciences, Inc. Polypeptides comprising a modified bacteriophage g3p amino acid sequence with reduced immunogenicity
BR112017011530A2 (pt) 2014-12-03 2018-03-13 Proclara Biosciences Inc polipeptídeos que compreendem uma sequência de aminoácidos g3p de bacteriófago modificada sem sinal de glicosilação

Similar Documents

Publication Publication Date Title
JP2015505823A5 (https=)
Eck et al. Regulation of TDP-43 phosphorylation in aging and disease
Scheckel et al. Prions, prionoids and protein misfolding disorders
Moreth et al. Passive anti-amyloid immunotherapy in Alzheimer's disease: What are the most promising targets?
Kim et al. BRI2 (ITM2b) inhibits Aβ deposition in vivo
JP6283366B2 (ja) アミロイド結合剤としてのバクテリオファージ融合タンパク質のｐ３の使用
Neff et al. Immunotherapy and naturally occurring autoantibodies in neurodegenerative disorders
JP6220344B2 (ja) アミロイド結合剤としてのバクテリオファージのｐ３の使用
Sharma et al. Effect of disease-associated P123H and V70M mutations on β-synuclein fibrillation
Roque et al. Histone H1 favors folding and parallel fibrillar aggregation of the 1–42 Amyloid-β Peptide
Eigenbrod et al. Substitutions of PrP N-terminal histidine residues modulate scrapie disease pathogenesis and incubation time in transgenic mice
Daude et al. Wild‐type Shadoo proteins convert to amyloid‐like forms under native conditions
Southwell et al. Antibody therapy in neurodegenerative disease
Barreca et al. Therapeutic Trajectories in Human Prion Diseases
Paganetti et al. Transgenic expression of β1 antibody in brain neurons impairs age-dependent amyloid deposition in APP23 mice
Zaccagnini In silico and in vitro screening of acridine and phenothiazine derivatives as anti-prion agents
CN120153082A (zh) 展示靶向β淀粉样蛋白的肽基序的M13噬菌体、其方法和用途
Noble Biochemical and Structural Studies of Prion Protein Misfolding
RS56559B1 (sr) Upotreba p3 fuzionih proteina bakteriofaga kao vezujućih agenasa amiloida
HK1213775B (en) Use of p3 of bacteriophage fusion proteins as amyloid binding agents
HK1197655B (en) Use of p3 of bacteriophage as amyloid binding agents
HK1197655A (en) Use of p3 of bacteriophage as amyloid binding agents